TY - JOUR
T1 - Transdermal drug delivery
T2 - Clinical aspects
AU - Kalia, Y. N.
AU - Merino, V.
AU - Guy, R. H.
N1 - Funding Information:
Financial support was provided by Novartis (Basel), Becton-Dickinson, and Electricité de France.
PY - 1998/4/1
Y1 - 1998/4/1
N2 - The delivery of drugs into and through the skin is a recognized and effective means of therapy for dermatologic, regional, and systemic disease. The selection of drug candidates and the rational design of suitable formulations depends upon the biological make-up of the skin's barrier, and the physicochemical interactions between the membrane, the delivery system technology, and the active agent. This article summarizes the state of the art and examines more recent developments that are the subject of considerable research at this time. In addition, the potential to use the skin as a portal for noninvasive clInical chemistry (e.g., for glucose monitoring in diabetics) is discussed.
AB - The delivery of drugs into and through the skin is a recognized and effective means of therapy for dermatologic, regional, and systemic disease. The selection of drug candidates and the rational design of suitable formulations depends upon the biological make-up of the skin's barrier, and the physicochemical interactions between the membrane, the delivery system technology, and the active agent. This article summarizes the state of the art and examines more recent developments that are the subject of considerable research at this time. In addition, the potential to use the skin as a portal for noninvasive clInical chemistry (e.g., for glucose monitoring in diabetics) is discussed.
UR - http://www.scopus.com/inward/record.url?scp=0031924387&partnerID=8YFLogxK
U2 - 10.1016/S0733-8635(05)70011-5
DO - 10.1016/S0733-8635(05)70011-5
M3 - Article
C2 - 9589202
AN - SCOPUS:0031924387
VL - 16
SP - 289
EP - 299
JO - Dermatologic Clinics
JF - Dermatologic Clinics
SN - 0733-8635
IS - 2
ER -
